Using ultrasound to detect nerve damage from oxaliplatin in cancer patients
Official title: A Pilot Study Using Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy
Run by Wake Forest University Health Sciences · NCT03958747 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if ultrasound can help find nerve damage caused by oxaliplatin in cancer patients with gastrointestinal cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Wake Forest University Health Sciences Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Winston-Salem, North Carolina) |
| Trial ID | NCT03958747 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with gastrointestinal or colorectal cancer who are currently or have previously received oxaliplatin-based chemotherapy and exhibit clinical symptoms of peripheral neuropathy.
✕Probably not a fit
Patients with a history of peripheral neuropathy prior to oxaliplatin treatment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot clinical trial evaluates the effectiveness of ultrasound in identifying oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer. The study compares the cross-sectional area of tibial motor and sural sensory nerves in affected patients against historical data from healthy adults. Additionally, it explores correlations between ultrasound findings and nerve conduction studies, self-reported neuropathy scales, and skin biopsy results. The trial aims to enhance diagnostic methods for neuropathy related to chemotherapy treatment.
Why it matters
Potential benefit: If successful, this study could lead to improved detection and management of chemotherapy-induced neuropathy in cancer patients.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in using ultrasound for nerve assessment, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Gastrointestinal cancer * Colorectal cancer (any stage) * Previously or currently receiving oxaliplatin -based chemotherapy. * Clinical symptoms of peripheral neuropathy noted in medical record and suspected to be secondary to oxaliplatin -based therapy. * Ability and willingness to understand and sign an informed consent. Exclusion Criteria: * Self-reported or documented history of pre-existing peripheral neuropathy prior to initiation of oxaliplatin chemotherapy. * Unable to provide history.
Where it's running
-
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States Recruiting
Study contacts
- Principal investigator: Roy Strowd, MD — Wake Forest University Health Sciences
- Study coordinator: Ashley Fansler, RN
- Email: arcarrol@wakehealth.edu
- Phone: 336-716-5440
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating RAS(ON) Inhibitors for Gastrointestinal Solid Tumors
This study is testing new RAS(ON) inhibitors combined with standard treatments to see if they can help people with certain types of gastrointestinal cancers that have RAS mutations.
-
Using nanoparticles to enhance radiation treatment for brain metastases
This study is testing if adding special nanoparticles to radiation therapy can help people with brain metastases get better results than radiation alone.
-
Personalized chemotherapy for abdominal cancer treatment
This study is testing a new way to personalize chemotherapy for patients with abdominal cancer by trying different treatments on their tumor samples before using them during surgery.
-
Collecting tumor samples to improve cancer treatment matching
This study is collecting tumor samples from patients with advanced cancer to see if analyzing their genes can help doctors find the best treatments for them.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.